Immunocore Holdings plc (IMCR)
|Net Income (ttm)||-156.07M|
|Day's Range||34.92 - 37.37|
|52-Week Range||18.43 - 40.96|
|Price Target||54.57 (+52.0%)|
|Earnings Date||Aug 10, 2022|
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase... [Read more...]
In 2021, IMCR's revenue was 26.52 million, a decrease of -11.93% compared to the previous year's 30.11 million. Losses were -131.52 million, 77.5% more than in 2020.Financial numbers in GBP Financial Statements
According to 11 analysts, the average rating for IMCR stock is "Buy." The 12-month stock price forecast is 54.57, which is an increase of 52.01% from the latest price.
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IMCR, UFCS, CWCO, HURN and FCN.
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR ...
Immunocore Appoints Sidd h art h Kaul to its Board of Directors
The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) ...
The UK Medicine s and Healthcare products Regulatory Agency ( MHRA ) , Australian Therapeutic Goods Administration (TGA) and Health Canada a pprove KIMMTRAK® ( tebentafusp ) for the treatment of unresec...
Immunocore (IMCR) signs a collaboration agreement with Sanofi to study the combination of Kimmtrak with the latter's SAR444245 for treating metastatic cutaneous melanoma. Shares up.
Wall Street Analysts See an 80% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move Thi...
The mean of analysts' price targets for Immunocore Holdings PLC Sponsored ADR (IMCR) points to an 80.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, st...
Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi's product candidate SAR444245, non-a...
Immunocore announce s c linical t rial c ollaboration with Sanofi to evaluate Sanofi's product candidate SAR 444 245 , non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous...
Immunocore to present at upcoming investor conferences
Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and Ne...
The latest geographic growth increases Medison's global footprint across 25 countries in four continents, further strengthening its commercial offering PETACH TIKVAH, Israel , May 23, 2022 /PRNewswire/ ...
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
Immunocore to present at the 21 st Annual Needham Healthcare Conference
With trials aimed at increasing addressable markets in the coming years, Legend and Immunocore could reward investors.
Immunocore Holdings PLC Sponsored ADR (IMCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near...
Wall Street Analysts See a 135% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move Thi...
The average of price targets set by Wall Street analysts indicates a potential upside of 134.8% in Immunocore Holdings PLC Sponsored ADR (IMCR). While the effectiveness of this highly sought-after metri...
Immunocore to present at Oppenheimer's 32 nd Annual Healthcare Conference
Immunocore to present at the SVB Leerink Global Healthcare Conference
The FDA has approved Immunocore Holdings plc (tebentafusp-tebn) for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM).
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uve...
Immunocore announces FDA approval of KIMMTRAK ® ( tebentafusp- tebn ) for the treatment of unresectable or metastatic uveal melanoma